deltatrials
Completed PHASE3 NCT00256854

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS)

Sponsor: GlaxoSmithKline

Conditions Restless Legs Syndrome Restless Legs Syndrome (RLS)
Interventions Ropinirole CR 2 mg Ropinirole CR 2 mg Placebo Ropinirole CR 3 mg Ropinirole CR 3 mg Placebo Ropinirole IR 1 mg Ropinirole IR 1 mg Placebo Ropinirole IR 2 mg Ropinirole IR 2 mg Placebo
Updated 8 times since 2017 Last updated: Nov 27, 2018 Started: Nov 14, 2005 Primary completion: Sep 21, 2006 Completion: Sep 21, 2006

This PHASE3 trial investigates Restless Legs Syndrome and Restless Legs Syndrome (RLS) and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE3

  2. Oct 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Oct 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Baton Rouge, United States, Bingham Farms, United States, Boca Raton, United States, Cherry Hill, United States, Columbia, United States, Dallas, United States, Dayton, United States, Greenville, United States, Laguna Hills, United States and 20 more location s